ANI Pharmaceuticals published an updated corporate investor presentation for November 2026 to its website. The presentation outlines the company's strategic transformation into a leading rare disease company, including its proposed acquisition of Egetis Therapeutics and growth strategies for products like Cortrophin Gel and ILUVIEN.
Ani Pharmaceuticals Sr. VP, General Counsel & Sec. Meredith Cook Sells $35.4K of Stock
Meredith Cook, Sr. VP, General Counsel & Sec., sold 500 shares of Ani Pharmaceuticals Inc at $70.80 a share, worth $35.4K in total on Nov 13, 2026. Shares held after the trade: 72,924 (-0.7%).
Ani Pharmaceuticals Signs $676M M&A Deal with Egetis Therapeutics AB
ANI Pharmaceuticals announced a recommended public cash offer to acquire all outstanding shares, convertibles, and warrants of Sweden-based Egetis Therapeutics AB. To finance the acquisition and refinance existing debt, ANI entered into a $676 million 364-day senior bridge credit facility with JPMorgan Chase Bank. The offer price is set at SEK 11.25 per share in cash.
ANI Pharmaceuticals reported a significant improvement in financial position for the period ended September 30, 2026, shifting from an accumulated deficit of $23.1 million to retained earnings of $66.3 million. Total assets increased to $1.57 billion, driven by a substantial rise in cash and cash equivalents to $420.8 million, while the company continues to focus on strategic growth through the proposed acquisition of Egetis Therapeutics AB.
ANI Pharmaceuticals reported Q3 2026 net revenues of $290.8 million, a 27.6% year-over-year increase driven by strong performance in its Rare Disease and Generics segments. The company narrowed its full-year revenue guidance and raised its adjusted EBITDA and EPS outlook while highlighting its pending acquisition of Egetis Therapeutics.
Term
Q3 2026
“In the third quarter, ANI delivered strong financial results, while advancing our transformation into a leading Rare Disease company. Cortrophin Gel delivered solid growth, driven by momentum from the gout expansion and continued progress in our existing specialties, while our Generics business continued to outperform.”
Nikhil Lalwani, President and CEO of ANI
“As we head into the end of the year, we are focused on delivering our 2026 financial guidance and advancing the proposed acquisition of Egetis toward closing. We are also executing multiple operational and strategic initiatives to achieve approximately 40% year-over-year growth in 2026 for Cortrophin and capture the significant multi-year growth opportunity ahead.”
Ani Pharmaceuticals SVP & CFO Stephen P. Carey Sells $208K of Stock
Stephen P. Carey, SVP & CFO, sold 2,850 shares of Ani Pharmaceuticals Inc at $72.87 a share, worth $208K in total on Oct 29, 2026. Shares held after the trade: 166,143 (-1.7%).
Ani Pharmaceuticals President & CEO Nikhil Lalwani Sells $388K of Stock
Nikhil Lalwani, President & CEO, sold 5,400 shares of Ani Pharmaceuticals Inc at $71.89 a share, worth $388K in total on Oct 15, 2026. Shares held after the trade: 333,689 (-1.6%).
Ani Pharmaceuticals Sr. VP, General Counsel & Sec. Meredith Cook Sells $36.8K of Stock
Meredith Cook, Sr. VP, General Counsel & Sec., sold 500 shares of Ani Pharmaceuticals Inc at $73.59 a share, worth $36.8K in total on Oct 13, 2026. Shares held after the trade: 73,424 (-0.7%).
Ani Pharmaceuticals SVP & CFO Stephen P. Carey Sells $208K of Stock
Stephen P. Carey, SVP & CFO, sold 2,850 shares of Ani Pharmaceuticals Inc at $73.00 a share, worth $208K in total on Sep 29, 2026. Shares held after the trade: 168,993 (-1.7%).